InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | RUBINSTEIN JULIE | President and COO | Sale | 19.0K | $14.23 | $271K | 377.8K | View ↗ | |
| 2026-04-24 | RUBINSTEIN JULIE | President and COO | Sale | 19.1K | $14.02 | $267K | 382.1K | View ↗ | |
| 2026-04-23 | RUBINSTEIN JULIE | President and COO | Sale | 19.1K | $13.74 | $262K | 386.5K | View ↗ | |
| 2026-04-22 | RUBINSTEIN JULIE | President and COO | Sale | 19.1K | $14.13 | $269K | 390.8K | View ↗ | |
| 2026-04-21 | RUBINSTEIN JULIE | President and COO | Sale | 30.9K | $14.66 | $454K | 395.1K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $277.0M+54.8% | $179.0M+5.1% | $170.3M-8.1% | $185.3M+20.1% | $154.3M |
| Cost of revenue | $71.4M-1.0% | $72.1M-4.6% | $75.6M+30.5% | $57.9M+17.5% | $49.3M |
| Research and development | $93.8M-8.9% | $103.0M-15.7% | $122.1M-13.9% | $141.8M-0.4% | $142.3M |
| Sales and marketing | $94.6M+11.6% | $84.8M-4.3% | $88.6M-7.3% | $95.6M+0.1% | $95.5M |
| General and administrative | $72.7M-0.1% | $72.8M-13.3% | $83.9M-5.2% | $88.5M+18.8% | $74.5M |
| Amortization of intangible assets | $1.7M-0.2% | $1.7M+0.2% | $1.7M+0.0% | $1.7M+0.0% | $1.7M |
| Impairment of long-lived assets | $0-100.0% | $7.2M-71.7% | $25.4M | — | — |
| Total operating expenses | $334.1M-2.2% | $341.5M-14.0% | $397.3M+3.1% | $385.5M+6.1% | $363.3M |
| Loss from operations | -$57.1M+64.9% | -$162.5M+28.4% | -$227.0M-13.4% | -$200.2M+4.2% | -$209.0M |
| Interest and other income, net | $9.4M-35.0% | $14.5M-6.4% | $15.5M+282.9% | $4.1M+143.2% | $1.7M |
| Interest expense | -$11.8M-1.7% | -$11.6M+16.1% | -$13.8M-225.6% | -$4.2M | — |
| Net loss | -$59.5M+62.7% | -$159.6M+29.2% | -$225.3M-12.4% | -$200.4M+3.3% | -$207.3M |
| Add: Net (income) loss attributable to noncontrolling interest | -$42K-140.8% | $103K+90.7% | $54K | — | — |
| Net loss attributable to Adaptive Biotechnologies Corporation | -$59.5M+62.7% | -$159.5M+29.2% | -$225.3M-12.5% | -$200.2M+3.4% | -$207.3M |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | -$390+63.9% | -$1K+30.8% | -$2K-11.4% | -$1K+5.4% | -$1K |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | -$390+63.9% | -$1K+30.8% | -$2K-11.4% | -$1K+5.4% | -$1K |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | $151.72B+3.1% | $147.10B+1.9% | $144.38B+1.3% | $142.52B+1.5% | $140.35B |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | $151.72B+3.1% | $147.10B+1.9% | $144.38B+1.3% | $142.52B+1.5% | $140.35B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Thermo Fisher ranks sixth by Quant as stock falls on Q1 results
Adaptive Biotechnologies: Strong Sequencing, Weak Margin Of Safety
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?